Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis

Waldthaler, Alexander; Schramm, Christoph; Bergquist, Annika

doi:10.1016/j.ejmg.2021.104231

Cited by 4 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…312 Other ERCP-based modalities including single-operator cholangioscopy with targeted biopsies, probe-based confocal laser endomicroscopy (pCLE) and endoscopic ultrasound for diagnosis of CCA in PSC are less studied. 304,[315][316][317] Cholangioscopy with targeted ductal biopsies can increase diagnostic accuracy. 304,317 One meta-analysis of different diagnostic modalities, including 21 studies altogether, compared bile duct brush cytology, FISH polysomy and trisomy and cholangioscopy with targeted biopsies.…”

Section: Ercp and Diagnosis Of Cca In Pscmentioning

confidence: 99%

EASL Clinical Practice Guidelines on sclerosing cholangitis

Chazouillères¹,

Beuers²,

Bergquist³

et al. 2022

Journal of Hepatology

136

View full text Add to dashboard Cite

Section: Ercp and Diagnosis Of Cca In Pscmentioning

confidence: 99%

EASL Clinical Practice Guidelines on sclerosing cholangitis

Chazouillères¹,

Beuers²,

Bergquist³

et al. 2022

Journal of Hepatology

136

View full text Add to dashboard Cite

“…Patients with PSC can develop “dominant strictures,” or focal narrowing defined at ERCP as stenosis with diameter ≤ 1.5 mm in the CBD and/or ≤ 1.0 mm in a hepatic duct within 2 cm of the ductal confluence[ 20 , 32 - 34 ]. Dominant strictures are clinically significant in light of their higher propensity for bacterial cholangitis and for underlying dysplasia or carcinoma[ 32 , 35 ]. A recent systematic review and meta-analysis of 21 studies found the that the pooled sensitivity and specificity of POC for diagnosis of CCA was 65% (95%CI: 35%-87%) and 97% (95%CI: 87%-99%), respectively[ 36 ].…”

Section: Common Applications Of Cholangioscopymentioning

confidence: 99%

Peroral cholangioscopy: Update on the state-of-the-art

Subhash¹,

Buxbaum²,

Tabibian³

2022

WJGE

View full text Add to dashboard Cite

Peroral cholangioscopy (POC) is an endoscopic procedure that allows direct intraductal visualization of the biliary tract. POC has emerged as a vital tool for indeterminate biliary stricture evaluation and treatment of difficult biliary stones. Over several generations of devices, POC has fulfilled additional clinical needs where other diagnostic or therapeutic modalities have been inadequate. With adverse event rates comparable to standard endoscopic retrograde cholangioscopy and unique technical attributes, the role of POC is likely to continue expand. In this frontiers article, we highlight the existing and growing clinical applications of POC as well as areas of ongoing research.

show abstract

“…In line with this, Spearman rank correlation showed a significant positive correlation between circulating suPAR levels and CRP values (p < 0.001; r = 0.641) (Figure 3B). Since up to 50% of patients with PSC develop inflammatory strictures in the biliary tree, which cause jaundice and bacterial cholangitis as well as predilection spots for development of neoplastic transformation, we next hypothesized that the presence of dominant stenoses (detected via endoscopic retrograde cholangiography-pancreatography (ERCP) and/or magnetic resonance cholangiopancreatography (MRCP) imaging) might be linked to higher suPAR levels [57][58][59][60]. However, suPAR levels of patients with and without dominant stenosis displayed similar suPAR concentrations (Figure 3C).…”

Section: Supar Is Elevated In Psc Patients With Acute Cholangitis But...mentioning

confidence: 99%

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Özdirik

Maibier

Scherf

et al. 2022

JCM

View full text Add to dashboard Cite

The soluble urokinase-type plasminogen activator receptor (suPAR) has evolved as a useful biomarker for different entities of chronic liver disease. However, its role in patients with primary sclerosing cholangitis (PSC) is obscure. We analyzed plasma levels of suPAR in 84 patients with PSC and compared them to 68 patients with inflammatory bowel disease (IBD) without PSC and to 40 healthy controls. Results are correlated with clinical records. suPAR concentrations were elevated in patients with PSC compared to patients with IBD only and to healthy controls (p < 0.001). Elevated suPAR levels were associated with the presence of liver cirrhosis (p < 0.001) and signs of portal hypertension (p < 0.001). suPAR revealed a high accuracy for the discrimination of the presence of liver cirrhosis comparable to previously validated noninvasive fibrosis markers (area under the curve (AUC) 0.802 (95%CI: 0.702–0.902)). Further, we demonstrated that suPAR levels may indicate the presence of acute cholangitis episodes (p < 0.001). Finally, despite the high proportion of PSC patients with IBD, presence of IBD and its disease activity did not influence circulating suPAR levels. suPAR represents a previously unrecognized biomarker for diagnosis and liver cirrhosis detection in patients with PSC. However, it does not appear to be confounded by intestinal inflammation in the context of IBD.

show abstract

Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis

Cited by 4 publications

References 57 publications

EASL Clinical Practice Guidelines on sclerosing cholangitis

EASL Clinical Practice Guidelines on sclerosing cholangitis

Peroral cholangioscopy: Update on the state-of-the-art

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Contact Info

Product

Resources

About